The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) increased by $0.2 on Friday to finish at $28.60, up 0.70 percent. The last five days have seen an average of 1,112,540 shares of common stock traded. 27 times new highs were reached in the current year, with a gain of $12.68. The average number of shares traded over the last 20 days was 1,534,495, while the average volume over the last 50 days totaled 1,700,714.
ACAD stock dropped -1.45% since last month. On 08/09/23, the company’s shares reached a one-month low of $26.10. The stock touched a high of $33.99 on 07/18/23, after rallying from a low of $13.73 in 52 weeks. The price of ACAD stock has risen by 79.65% or $12.68 this year, reaching a new high 27 times. Still, the stock price is down -15.86% from the 52-week high.
Insider Transactions
ACAD stock investors should be aware that ACADIA Pharmaceuticals Inc. (ACAD) stock had its last reported insider trading activity 7 days ago on Aug 21. On Aug 21, EVP, Chief Financial Officer Schneyer Mark C. sold 10,000 shares at $29.00 each. This transaction resulted in the insider making $289,970. On Jul 14, DAVIS STEPHEN sold 100,000 shares at a price of US$30.04. After the transaction, the insider now owns 36,695 shares. CEO DAVIS STEPHEN had earlier sold 55,104 shares on Jul 12 for $25.05 a share. The transaction was completed for $1,380,449.
Valuation Metrics
Beta for the stock is 0.56. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 8.44, the price-to-book (PB) ratio of 11.82.
Financial Health
For the three months ended June 30, ACADIA Pharmaceuticals Inc.’s quick ratio was 2.60, while its current ratio was 2.60, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 97.50% percent. ACADIA Pharmaceuticals Inc.’s EBITDA margin for the year ended June 30 was -42.84%, whereas its operating margin stood at -23.10% for the same period. Based on annual data, it had gross profit of $507.07 million and revenue of $517.24 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ACAD’s return on assets (ROA) during the last 12 months has been -17.80%. There was a -56.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -27.80%.
Earnings Surprise
According to ACADIA Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 30. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $165.24 million, while revenues rose by 18.57% to $118.46 million. It was predicted that ACADIA Pharmaceuticals Inc.’s quarterly earnings would be $0.01, but it ended up being -$0.08, beating the consensus by 112.50%. EBITDA was $3.31 million for the quarter. At the end of ACADIA Pharmaceuticals Inc.’s most recent quarter ended June 30, its liabilities totaled 246.98 million, while its total debt was $58.84 million. Equity owned by shareholders amounts to $163.73 million.
Technical Picture
Here’s a quick look at ACADIA Pharmaceuticals Inc.’s (ACAD) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 50.43%, suggesting the stock is Neutral, with a 35.27% historical volatility rate.
The stochastic %K and %D were 55.75% and 63.10% respectively, while the average true range (ATR) was 0.96. Based on the 14-day stochastic reading of 56.96%, the RSI (14) reading is 52.24%. On the 9-day MACD Oscillator, the stock is at -0.48, and the 14-day reading is at 0.22.
Analyst Ratings
In its most recent analyst report, Guggenheim raised its rating on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned ACADIA Pharmaceuticals Inc. (ACAD) an Overweight rating. ACAD is a stock that is recommended for selling by 1 brokerage firm, while 8 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 8 others recommend it as a buy.
What is ACAD’s price target for the next 12 months?
The current consensus forecast for the stock is between $13.00 and $42.00, with a median target price of $33.00. In analyzing these forecasts, the average price target given by analysts for ACADIA Pharmaceuticals Inc. (ACAD) is $31.13.
